Flerie AB (publ) (STO:FLERIE)

Sweden flag Sweden · Delayed Price · Currency is SEK
21.10
+0.20 (0.96%)
Jun 12, 2026, 4:50 PM CET
Market Cap2.01B -39.7%
Revenue (ttm)1.80M -21.7%
Net Income-567.30M
EPS-6.35
Shares Out 95.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,438
Open21.00
Previous Close20.90
Day's Range20.90 - 21.40
52-Week Range20.80 - 41.74
Beta-0.48
Analystsn/a
Price Targetn/a
Earnings DateJul 9, 2026

About Flerie AB

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol FLERIE
Full Company Profile

Financial Performance

In 2025, Flerie AB's revenue was 2.50 million, a decrease of -3.85% compared to the previous year's 2.60 million. Losses were -756.90 million, 232.0% more than in 2024.

Financial Statements

News

Flerie AB Earnings Call Transcript: Q1 2026

Q1 2026 saw strong financing, raising SEK 208 million and boosting NAV to SEK 3.7 billion. The investment ratio reached 2.33x, with significant R&D progress and a completed Lipum merger, despite challenging market conditions.

2 months ago - Transcripts

Flerie AB Quarterly report: Q1 2026

Flerie AB has published its Q1 2026 quarterly earnings report on April 15, 2026.

2 months ago - Filings

Flerie AB Slides: Q1 2026

Flerie AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 15, 2026.

2 months ago - Filings

Flerie AB Earnings Call Transcript: Q4 2025

Q4 saw a 14% NAV decline to SEK 3.4 billion, driven by write-downs in key holdings and strategic divestment of the LP segment. Management remains optimistic, citing strong clinical progress, robust cash reserves, and a focus on direct investments for long-term value creation.

5 months ago - Transcripts

Flerie AB Annual report: Q4 2025

Flerie AB has published its Q4 2025 annual report on January 21, 2026.

5 months ago - Filings

Flerie AB Quarterly report: Q4 2025

Flerie AB has published its Q4 2025 quarterly earnings report on January 21, 2026.

5 months ago - Filings

Flerie AB Earnings Call Transcript: Q3 2025

NAV declined to SEK 3.9 billion in Q3, impacted by write-downs and share redemptions. Key portfolio milestones included successful capital raises, a merger, and new strategic partnerships, while market conditions showed early signs of recovery.

8 months ago - Transcripts

Flerie AB Quarterly report: Q3 2025

Flerie AB has published its Q3 2025 quarterly earnings report on October 22, 2025.

8 months ago - Filings

Flerie AB Earnings Call Transcript: Q2 2025

Celebrating its IPO anniversary, the company reported a SEK 4.1 billion NAV, strong cash position, and portfolio growth driven by clinical and commercial stage investments. Outperformed key indices despite a tough macro environment, with innovative M&A and capital management strategies.

11 months ago - Transcripts

Flerie AB Quarterly report: Q2 2025

Flerie AB has published its Q2 2025 quarterly earnings report on July 31, 2025.

11 months ago - Filings